Research Update
Others Research
RESEARCH CHRONICLES
What’s Shaping Eye Care?
Research Update#2
Advancing Wet Age-Related Macular Degeneration
Our Focus
Our team, led by Dr. Jay Sheth, collaborated across multiple eye care centers in India to study the effects of a newer treatment called brolucizumab, an injection given inside the eye, for treating neovascular age-related macular degeneration (nAMD). This condition can cause severe vision loss, and the study aimed to evaluate the injection's effectiveness and safety over a year.
What is it about?
nAMD is a major cause of vision problems in older adults. It occurs when abnormal blood vessels grow in the retina, leaking fluid and damaging vision. Our study analyzed the records of 82 patients treated with brolucizumab injections. After 52 weeks, most patients experienced sustained visual improvements and significant reductions in retinal swelling, even among those previously unresponsive to other treatments, highlighting the injection's effectiveness in managing disease progression. On average, patients needed fewer injections (around 5 in a year), which could make treatment less burdensome.
Why it matters
Age-related macular degeneration is a leading cause of blindness in older adults, and frequent injections often burden patients and caregivers. By requiring fewer injections while delivering lasting results, brolucizumab offers a more convenient option for patients, many of whom struggle with frequent doctor visits. The findings are especially encouraging for people who didn’t benefit from previous treatments, as this injection offers hope for improved vision and quality of life.
Citation
SChakraborty D, Maiti A, Sheth JU, Mondal S, Boral S, Nandi K, Sinha TK, Das A. Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study – Fifty-Two-Week Outcomes. Clin Ophthalmol. 2022;16:4303-4313
DOI: https://doi.org/10.2147/OPTH.S395577
